Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital ExperienceTM, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO- NAFLD-1 TrialNovember 13, 2020
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and HighlightsNovember 5, 2020
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 TrialOctober 1, 2020
Press Release History